In the new parallel phase I cohort, the intraperitoneal delivery of Mcy-M11 will be assessed at escalating doses in additional patients with relapsed/refractory ovarian cancer and malignant peritoneal mesothelioma. A preconditioning regimen of cyclophosphamide will be added prior to Mcy-M11 infusion in this cohort, which will progress independently from the ongoing evaluation in the existing cohort that is not receiving a preconditioning regimen.

The company noted that the phase I trial will also allow, where indicated, for multiple treatment cycles in both future preconditioning and no-preconditioning patients.

In addition, Massachusetts General Hospital and Hackensack University Medical Center have now joined existing trial sites at the U.S. National Cancer Institute and Washington University at St. Louis. Preliminary clinical data is expected from the trial in the second half of this year.